{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T12:24:41Z","timestamp":1783340681612,"version":"3.54.6"},"reference-count":30,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adolescent venous thromboembolism (VTE) has unique challenges in management, complications, and compliance to anticoagulants. Direct oral anticoagulants (DOACs) have been approved for pediatric VTE management, with an increasing use especially in adolescents. Primary objective is to evaluate the safety and efficacy of DOAC therapy in adolescent VTE. Secondary objectives include adverse events, bleeding events, and overall mortality. A SR protocol was registered in PROSPERO 2022 (CRD42022363928). Databases were searched from inception to September 22, 2022. Studies with children aged 10\u201318\u00a0years, VTE diagnosis, DOAC therapy, randomized control trials (RCTs), cohort, and relevant study types were included. Studies including prophylaxis, non\u2010DOAC therapy, arterial thrombosis, age outliers, non\u2010relevant study types were excluded. Findings are reported in accordance to PRISMA 2020. Nine reports from five studies, published between 2016 and 2022, were included. Rivaroxaban was the most common DOAC. VTE recurrence was 0.02% in the rivaroxaban phase III trial and one patient in the dabigatran phase IIb\/III trial. Complete\/partial thrombus resolution (CR\/PR) was 76.6% in the rivaroxaban phase III trial, and 83.9% in the dabigatran phase IIb\/III trial. CR\/PR was found to be 68.4% in Dhaliwal et\u00a0al. study and 83.3% in Hassan et\u00a0al. study. Major bleeding occurred in one patient. Headache and gastrointestinal symptoms were commonly seen. All\u2010cause mortality occurred in a patient due to cancer progression. DOAC therapy in adolescent VTE had CR\/PR in two\u2010thirds of the patients, with low incidence of VTE recurrence and major bleeding. As there are only two randomized controlled trial (RCTs), future adolescents\u2019 studies are required to validate our results.<\/jats:p>","DOI":"10.1002\/pbc.31131","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T12:53:34Z","timestamp":1718888014000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Direct oral anticoagulant therapy in adolescent venous thromboembolism: A systematic review"],"prefix":"10.1002","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1176-8952","authenticated-orcid":false,"given":"Shaikha","family":"Alqahtani","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Pediatric Hematology and Oncology The University of Texas MD Anderson Cancer Center, Children's Cancer Hospital  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen DiValerio","family":"Gibbs","sequence":"additional","affiliation":[{"name":"Department of Pediatrics Baylor College of Medicine  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie A.","family":"Montanez","sequence":"additional","affiliation":[{"name":"Gulf States Hemophilia and Thrombophilia Center Division of Hematology Department of Pediatrics McGovern Medical School and University of Texas Health Science Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate J.","family":"Krause","sequence":"additional","affiliation":[{"name":"Research Medical Library, The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Heleen","family":"van Ommen","sequence":"additional","affiliation":[{"name":"International Pediatric Thrombosis Network, Department Pediatric Hematology Erasmus MC Sophia Children's Hospital  Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi V.","family":"Srivaths","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Pediatric Hematology and Oncology The University of Texas MD Anderson Cancer Center, Children's Cancer Hospital  Houston Texas USA"},{"name":"Gulf States Hemophilia and Thrombophilia Center Division of Hematology Department of Pediatrics McGovern Medical School and University of Texas Health Science Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2021-054649"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-0768"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.5045\/br.2016.51.3.149"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41390-022-02294-3"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.860369"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/BPB.0000000000000053"},{"issue":"6","key":"e_1_2_12_8_1","first-page":"1089","article-title":"Pulmonary embolism in adolescents","volume":"125","author":"Ma QB","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001847"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.4059"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017559"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30219-4"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30368-9"},{"key":"e_1_2_12_14_1","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews [Declaracion PRISMA 2020: una guia actualizada para la publicacion de revisiones sistematicas]","volume":"46","author":"Page MJ","year":"2022","journal-title":"Rev Panam Salud Publica"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6890"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003244"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30161-9"},{"issue":"3","key":"e_1_2_12_22_1","first-page":"461","article-title":"Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. An open\u2010label phase IIa study","volume":"116","author":"Halton JM","year":"2016","journal-title":"Thromb Haemost"},{"key":"e_1_2_12_23_1","doi-asserted-by":"crossref","unstructured":"MichalskiF SMLT Beyer\u2010WestendorfJ.Venous thromboembolism treatment with rivaroxaban in adolescents\u2014preliminary findings from the prospective Dresden NOAC Registry (NCT01588119).2016. doi:10.1055\/s-0039-1680146","DOI":"10.1055\/s-0039-1680146"},{"issue":"01","key":"e_1_2_12_24_1","first-page":"S1","article-title":"Treatment of VTE with rivaroxaban in adolescents\u2014preliminary findings from the prospective Dresden NOAC Registry (NCT01588119)","volume":"39","author":"Marten S","year":"2019","journal-title":"Hamostaseologie"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2022.11.027"},{"issue":"2","key":"e_1_2_12_26_1","article-title":"Resolution rates of provoked deep vein thrombosis and pulmonary embolism in pediatric patients managed at a tertiary care center [abstract]","volume":"5","author":"Dhaliwal M","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.03975.x"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000840"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1590\/1984-0462\/;2017;35;4;00008"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(00)90005-2"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.399"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.31131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T03:35:21Z","timestamp":1721878521000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.31131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1002\/pbc.31131"],"URL":"https:\/\/doi.org\/10.1002\/pbc.31131","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]},"assertion":[{"value":"2023-12-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e31131"}}